SHANGHAI YIZHONG
68809136.311.59% ( +0.57 )
SHANGHAI YIZHONG (688091)
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitax...
- Open
- 36.01
- High
- 37.38
- Low
- 36.01
- Prev. Close
- 35.74
- Volume
- 28.93K
- Turnover
- 106.27M
- Avg Price
- 36.74
- Bid/Ask Ratio
- --
- Amplitude
- 3.83%
- 52wk High
- 83.60
- Volume Ratio
- 0.55
- Turnover Ratio
- 1.40%
News
- Wallstreetcn · Jan 8 at 11:26 PM
The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit
- Zhitong · Sep 14, 2025 at 10:44 PM
HuaYuan Securities: The potential of PD1/VEGF/IL-2 is promising, insisting on innovative drugs as the main line for the whole year
- Zhitong · Sep 14, 2025 at 08:43 PM
Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up
- Zhitong · Sep 12, 2025 at 04:09 AM
SHANGHAI YIZHONG plans to repurchase shares for 30 million to 35 million yuan
- Zhitong · Sep 11, 2025 at 02:47 AM
SHANGHAI YIZHONG: The chairman proposed to repurchase shares worth 30 million to 35 million yuan
- Zhitong · Aug 19, 2025 at 12:45 AM
Some A-share biopharmaceutical stocks weakened, SHANGHAI YIZHONG fell over 7%, INNOCARE fell over 5%
